Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
RESEARCH TOOLSreports
Orchestra BioMed Holdings (OBIO) Stock Price & Analysis
52 Followers
OBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.22 - $11.69
Previous Close$8.53
Volume103.23K
Average Volume (3M)124.80K
Market Cap
$305.28M
Enterprise Value$231.86M
Total Cash (Recent Filing)$75.04M
Total Debt (Recent Filing)$1.62M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 08, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding35,788,497
10 Day Avg. Volume84,178
30 Day Avg. Volume124,804
Standard Deviation0.25
R-Squared0.00674
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.32
Price to Sales (P/S)364.81
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue114.27
Enterprise Value/Gross Profit84.01
Enterprise Value/Ebitda-4.17
Forecast
1Y Price Target
$17.50Price Target Upside105.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Orchestra BioMed Holdings News
PremiumCompany Announcements
Orchestra BioMed Showcases Progress at Investor Conferences
Bulls Say, Bears Say
Bulls Say
Clinical DataNew clinical data showed significant decreases in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and cardiac workload, without compromising cardiac output or contractility.
Clinical TrialsThe company's lead product, BackBeat CNT for hypertensive pacemaker patients is currently enrolling patients in its pivotal clinical study.
Product EfficacyBackBeat CNT is designed to 'substantially' reduce blood pressure in patients with hypertension.
Bears Say
Cash BurnCash burn from operations during the quarter was -$13.1 mm.
Cash BurnCash burn from operations during the quarter was -$11.0 mm, and for the full year was -$46.1 mm.
Cash PositionThe company ended the quarter with $75 mm in cash, cash equivalents, and short term investments, compared to $88 mm at the end of last year.
---
Ownership Overview
58.00% Insiders
6.65% Mutual Funds
30.16% Other Institutional Investors
5.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $4.22 and its highest was $11.69 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Currently, no data Available
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Aug 08, 2024 which is in 22 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on May 13, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.017.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -$0.4.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 35,788,498 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went up 13.043%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Among the largest hedge funds holding Orchestra BioMed Holdings’s share is Perceptive Advisors LLC. It holds Orchestra BioMed Holdings’s shares valued at 13M.
---
Orchestra BioMed Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (105.16% Upside)
$17.50 (105.16% Upside)
Hedge Fund Trend
Increased
By 113.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $35.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.28%
12-Months-Change
Fundamentals
Return on Equity
-65.81%
Trailing 12-Months
Asset Growth
-39.37%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Health Sciences Acquisitions Corp 2 is a blank check company.
---
OBIO Stock 12 Month Forecast
Average Price Target
$17.50
▲(105.16% Upside)
Technical Analysis
Cidara Therapeutics
―
Aptose Biosciences
―
Molecular Templates
―
Jaguar Animal Health
―
Best Analysts Covering OBIO
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+26.26%
assigned a buy rating 2 months ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +26.26% per trade.
---